Selagine
Private Company
Funding information not available
Overview
Selagine is a private, preclinical-stage biotech developing innovative biologic and antibody-based therapies for ocular surface diseases. Its lead asset, SLG-100, is a clinical-stage biologic eye drop for Dry Eye Disease (DED) with a novel mechanism targeting cytokines and autoantibodies, while SLG-200 is a novel ophthalmic antibiotic for bacterial keratitis. The company is based in Chicago, operates from UIC's incubator, and is led by its founder, Dr. Sandeep Jain, supported by a small team of scientific and business advisors.
Technology Platform
Utilizes pooled human immune globulins containing natural anti-cytokine and anti-idiotypic antibodies for broad-spectrum anti-inflammatory and immunomodulatory effects in ocular diseases.
Opportunities
Risk Factors
Competitive Landscape
In Dry Eye Disease, SLG-100 competes with FDA-approved T-cell modulators (Restasis, Cequa, Xiidra) and a pipeline of new mechanisms. Its differentiation lies in directly targeting cytokines and autoantibodies. In infectious keratitis, SLG-200 would enter a market with existing topical antibiotics, where novelty and efficacy against resistant strains would be key competitive factors.